Metabolomics represents a more recent addition to the range of omics tools, which are increasingly used in clinical applications. By measuring the composition of small molecules in tissues, blood or urine, it provides a sensitive molecular readout often associated with disease and its states, especially in cancer. Changes in metabolism related to cancer are increasingly well understood and are seen as a major hallmark of cancer. This review covers metabolomics used in human breast cancers, with a focus on its application in clinical diagnostics. There are clear indications that metabolomics could be a useful addition to currently established clinical diagnostic tools for breast cancer, including the possibility to detect cancer and to predict treatment responses and survival rates from blood and tissue samples.

Keywords:
Biomarkers, Breast cancer, Metabolism, Metabolomics
1.
Ferlay J, Shin H-R, Bray F, Forman D, Mathers C, Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127:2893-2917.
2.
Duffy MJ: Predictive markers in breast and other cancers: a review. Clin Chem 2005;51:494-503.
3.
Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-792.
4.
Carney WP, Neumann R, Lipton A, Leitzel K, Ali S, Price CP: Potential clinical utility of serum HER-2/neu oncoprotein concentrations in patients with breast cancer. Clin Chem 2003;49:1579-1598.
5.
Lee JS, Park S, Park JM, Cho JH, Kim SI, Park B-W: Elevated levels of serum tumor markers CA 15-3 and CEA are prognostic factors for diagnosis of metastatic breast cancers. Breast Cancer Res Treat 2013;141:477-484.
6.
Duffy MJ: Serum tumor markers in breast cancer: are they of clinical value? Clin Chem 2006;52:345-351.
7.
Ren J, Agata N, Chen D, Li Y, Yu W, Huang L, et al: Human MUC1 carcinoma-associated protein confers resistance to genotoxic anticancer agents. Cancer Cell 2004;5:163-175.
8.
Beggs AD, Dilworth MP: Surgery in the era of the 'omics revolution. Br J Surg 2015;102:e29-e40.
9.
Andreopoulou E, Hortobagyi GN: Prognostic factors in metastatic breast cancer: successes and challenges toward individualized therapy. J Clin Oncol 2008;26:3660-3662.
10.
Hanahan D, Weinberg RA: Hallmarks of cancer: the next generation. Cell 2011;144:646-674.
11.
DeBerardinis RJ, Sayed N, Ditsworth D, Thompson CB: Brick by brick: metabolism and tumor cell growth. Curr Opin Genet Dev 2008;18:54-61.
12.
Warburg O, Wind F, Negelein E: Über den Stoffwechsel von Tumoren im Körper. Klin Wochenschr 1926;5:829-832.
13.
Warburg O: On the origin of cancer cells. Science 1956;123:309-314.
14.
Koppenol WH, Bounds PL, Dang CV: Otto Warburg's contributions to current concepts of cancer metabolism. Nat Rev Cancer 2011;11:325-337.
15.
Hsu PP, Sabatini DM: Cancer cell metabolism: Warburg and beyond. Cell 2008;134:703-707.
16.
Bathen TF, Geurts B, Sitter B, Fjøsne HE, Lundgren S, Buydens LM, et al: Feasibility of MR metabolomics for immediate analysis of resection margins during breast cancer surgery. PLoS One 2013;8:e61578.
17.
Gribbestad IS, Fjösne HE, Haugen OA, Nilsen G, Krane J, Petersen SB, et al: In vitro proton NMR spectroscopy of extracts from human breast tumours and non-involved breast tissue. Anticancer Res 1993;13:1973-1980.
18.
Mackinnon WB, Barry PA, Malycha PL, Gillett DJ, Russell P, Lean CL, et al: Fine-needle biopsy specimens of benign breast lesions distinguished from invasive cancer ex vivo with proton MR spectroscopy. Radiology 1997;204:661-666.
19.
Cheng LL, Chang I-W, Smith BL, Gonalez LG: Evaluating human breast ductal carcinomas with high-resolution magic-angle spinning proton magnetic resonance spectroscopy. J Magn Reson 1998;135:194-202.
20.
Sitter B, Lundgren S, Bathen TF, Halgunset J, Fjosne HE, Gribbestad IS: Comparison of HR MAS MR spectroscopic profiles of breast cancer tissue with clinical parameters. NMR Biomed 2006;19:30-40.
21.
Giskeødegård GF, Grinde MT, Sitter B, Axelson DE, Lundgren S, Fjøsne HE, et al: Multivariate modeling and prediction of breast cancer prognostic factors using MR metabolomics. J Proteome Res 2010;9:972-979.
22.
Borgan E, Sitter B, Lingjæerde OC, Johnsen H, Lundgren S, Bathen TF, et al: Merging transcriptomics and metabolomics - advances in breast cancer profiling. BMC Cancer 2010;10:628.
23.
Li M, Song Y, Cho N, Chang JM, Koo HR, Yi A, et al: An HR-MAS MR metabolomics study on breast tissues obtained with core needle biopsy. PLoS One 2011;6:e25563.
24.
Moestue SA, Borgan E, Huuse EM, Lindholm EM, Sitter B, Børresen-Dale A-L, et al: Distinct choline metabolic profiles are associated with differences in gene expression for basal-like and luminal-like breast cancer xenograft models. BMC Cancer 2010;10:433.
25.
Morse DL, Carroll D, Day S, Gray H, Sadarangani P, Murthi S, et al: Characterization of breast cancers and therapy response by MRS and quantitative gene expression profiling in the choline pathway. NMR Biomed 2009;22:114-127.
26.
Aboagye EO, Bhujwalla ZM: Malignant transformation alters membrane choline phospholipid metabolism of human mammary epithelial cells. Cancer Res 1999;59:80-84.
27.
Tang X, Lin C-C, Spasojevic I, Iversen ES, Chi J-T, Marks JR: A joint analysis of metabolomics and genetics of breast cancer. Breast Cancer Res 2014;16:415.
28.
Sitter B, Bathen TF, Singstad TE, Fjøsne HE, Lundgren S, Halgunset J, et al: Quantification of metabolites in breast cancer patients with different clinical prognosis using HR MAS MR spectroscopy. NMR Biomed 2010;23:424-431.
29.
Cao MD, Sitter B, Bathen TF, Bofin A, Lønning PE, Lundgren S, et al: Predicting long-term survival and treatment response in breast cancer patients receiving neoadjuvant chemotherapy by MR metabolic profiling. NMR Biomed 2012;25:369-378.
30.
Cao MD, Giskeødegård GF, Bathen TF, Sitter B, Bofin A, Lønning PE, et al: Prognostic value of metabolic response in breast cancer patients receiving neoadjuvant chemotherapy. BMC Cancer 2012;12:39.
31.
Giskeødegård GF, Lundgren S, Sitter B, Fjøsne HE, Postma G, Buydens LMC, et al: Lactate and glycine - potential MR biomarkers of prognosis in estrogen receptor-positive breast cancers. NMR Biomed 2012 Nov;25:1271-1279.
32.
Choi JS, Baek H-M, Kim S, Kim MJ, Youk JH, Moon HJ, et al: Magnetic resonance metabolic profiling of breast cancer tissue obtained with core needle biopsy for predicting pathologic response to neoadjuvant chemotherapy. PLoS One 2013;8:e83866.
33.
Chan ECY, Koh PK, Mal M, Cheah PY, Eu KW, Backshall A, et al: Metabolic profiling of human colorectal cancer using high-resolution magic angle spinning nuclear magnetic resonance (HR-MAS NMR) spectroscopy and gas chromatography mass spectrometry (GC/MS). J Proteome Res 2009;8:352-361.
34.
Jiménez B, Mirnezami R, Kinross J, Cloarec O, Keun HC, Holmes E, et al: 1H HR-MAS NMR spectroscopy of tumor-induced local metabolic ‘field-effects' enables colorectal cancer staging and prognostication. J Proteome Res 2013;12:959-968.
35.
Kim S, Lee S, Maeng YH, Chang WY, Hyun JW, Kim S: Study of metabolic profiling changes in colorectal cancer tissues using 1D 1H HR-MAS NMR spectroscopy. Bull Korean Chem Soc 2013;34:1467-1472.
36.
Mirnezami R, Jiménez B, Li JV, Kinross JM, Veselkov K, Goldin RD, et al: Rapid diagnosis and staging of colorectal cancer via high-resolution magic angle spinning nuclear magnetic resonance (HR-MAS NMR) spectroscopy of intact tissue biopsies. Ann Surg 2014;259:1138-1149.
37.
Somashekar BS, Kamarajan P, Danciu T, Kapila YL, Chinnaiyan AM, Rajendiran TM, et al: Magic angle spinning NMR-based metabolic profiling of head and neck squamous cell carcinoma tissues. J Proteome Res 2011;10:5232-5241.
38.
Schwarz AJ, Maisey NR, Collins DJ, Cunningham D, Huddart R, Leach MO: Early in vivo detection of metabolic response: a pilot study of 1H MR spectroscopy in extracranial lymphoma and germ cell tumours. Br J Radiol 2002;75:959-966.
39.
Bartella L, Morris EA, Dershaw DD, Liberman L, Thakur SB, Moskowitz C, et al: Proton MR spectroscopy with choline peak as malignancy marker improves positive predictive value for breast cancer diagnosis: preliminary study. Radiology 2006;239:686-692.
40.
Tozaki M, Sakamoto M, Oyama Y, O'uchi T, Kawano N, Suzuki T, et al: Monitoring of early response to neoadjuvant chemotherapy in breast cancer with 1H MR spectroscopy: comparison to sequential 2-[18F]-fluorodeoxyglucose positron emission tomography. J Magn Reson Imaging 2008;28:420-427.
41.
Baek H-M, Chen J-H, Nie K, Yu HJ, Bahri S, Mehta RS, et al: Predicting pathologic response to neoadjuvant chemotherapy in breast cancer by using MR imaging and quantitative 1H MR spectroscopy. Radiology 2009;251:653-662.
42.
Brockmöller SF, Bucher E, Müller BM, Budczies J, Hilvo M, Griffin JL, et al: Integration of metabolomics and expression of glycerol-3-phosphate acyltransferase (GPAM) in breast cancer - link to patient survival, hormone receptor status, and metabolic profiling. J Proteome Res 2012;11:850-860.
43.
Budczies J, Denkert C, Müller BM, Brockmöller SF, Klauschen F, Györffy B, et al: Remodeling of central metabolism in invasive breast cancer compared to normal breast tissue - a GC-TOFMS based metabolomics study. BMC Genomics 2012;13:334.
44.
Budczies J, Pfitzner BM, Györffy B, Winzer K-J, Radke C, Dietel M, et al: Glutamate enrichment as new diagnostic opportunity in breast cancer: glutamate and glutamine in breast cancer. Int J Cancer 2015;136:1619-1628.
45.
Hilvo M, Denkert C, Lehtinen L, Müller B, Brockmöller S, Seppänen-Laakso T, et al: Novel theranostic opportunities offered by characterization of altered membrane lipid metabolism in breast cancer progression. Cancer Res 2011;71:3236-3245.
46.
Asiago VM, Alvarado LZ, Shanaiah N, Gowda GAN, Owusu-Sarfo K, Ballas RA, et al: Early detection of recurrent breast cancer using metabolite profiling. Cancer Res 2010;70:8309-8318.
47.
Wei S, Liu L, Zhang J, Bowers J, Gowda GAN, Seeger H, et al: Metabolomics approach for predicting response to neoadjuvant chemotherapy for breast cancer. Mol Oncol 2013;7:297-307.
48.
Oakman C, Tenori L, Claudino WM, Cappadona S, Nepi S, Battaglia A, et al: Identification of a serum-detectable metabolomic fingerprint potentially correlated with the presence of micrometastatic disease in early breast cancer patients at varying risks of disease relapse by traditional prognostic methods. Ann Oncol 2011;22:1295-1301.
49.
Tenori L, Oakman C, Claudino WM, Bernini P, Cappadona S, Nepi S, et al: Exploration of serum metabolomic profiles and outcomes in women with metastatic breast cancer: a pilot study. Mol Oncol 2012;6:437-444.
50.
Tenori L, Oakman C, Morris PG, Gralka E, Turner N, Cappadona S, et al: Serum metabolomic profiles evaluated after surgery may identify patients with oestrogen receptor negative early breast cancer at increased risk of disease recurrence. Results from a retrospective study. Mol Oncol 2015;9:128-139.
51.
Jobard E, Pontoizeau C, Blaise BJ, Bachelot T, Elena-Herrmann B, Trédan O: A serum nuclear magnetic resonance-based metabolomic signature of advanced metastatic human breast cancer. Cancer Lett 2014;343:33-41.
52.
Nicholson JK, Lindon JC: Systems biology: metabonomics. Nature 2008;455:1054-1056.
53.
Chen Y, Zhang R, Song Y, He J, Sun J, Bai J, et al: RRLC-MS/MS-based metabonomics combined with in-depth analysis of metabolic correlation network: finding potential biomarkers for breast cancer. Analyst 2009;134:2003.
54.
Henneges C, Bullinger D, Fux R, Friese N, Seeger H, Neubauer H, et al: Prediction of breast cancer by profiling of urinary RNA metabolites using Support Vector Machine-based feature selection. BMC Cancer 2009;9:104.
55.
Nam H, Chung BC, Kim Y, Lee K, Lee D: Combining tissue transcriptomics and urine metabolomics for breast cancer biomarker identification. Bioinformatics 2009;25:3151-3157.
56.
Kim Y, Koo I, Jung BH, Chung BC, Lee D: Multivariate classification of urine metabolome profiles for breast cancer diagnosis. BMC Bioinformatics 2010;11:S4.
57.
Slupsky CM, Steed H, Wells TH, Dabbs K, Schepansky A, Capstick V, et al: Urine metabolite analysis offers potential early diagnosis of ovarian and breast cancers. Clin Cancer Res 2010;16:5835-5841.
58.
Woo HM, Kim KM, Choi MH, Jung BH, Lee J, Kong G, et al: Mass spectrometry based metabolomic approaches in urinary biomarker study of women's cancers. Clin Chim Acta 2009;400:63-69.
59.
Yu L, Jiang C, Huang S, Gong X, Wang S, Shen P: Analysis of urinary metabolites for breast cancer patients receiving chemotherapy by CE-MS coupled with on-line concentration. Clin Biochem 2013;46:1065-1073.
60.
Yamazaki H, Inoue T, Koizumi M, Tanaka E, Yoshioka Y, Nakamura H, et al: Urinary 8-hydroxy-2′-deoxyguanosine excretion as a biomarker for estimating DNA oxidation in patients undergoing external radiotherapy and/or brachytherapy. Oncol Rep 2005;13:847-851.
61.
Mountford C, Somorjai R, Malycha P, Gluch L, Lean C, Russell P, et al: Diagnosis and prognosis of breast cancer by magnetic resonance spectroscopy of fine-needle aspirates analysed using a statistical classification strategy. Br J Surg 2001;88:1234-1240.
62.
Budczies J, Brockmöller SF, Müller BM, Barupal DK, Richter-Ehrenstein C, Kleine-Tebbe A, et al: Comparative metabolomics of estrogen receptor positive and estrogen receptor negative breast cancer: alterations in glutamine and beta-alanine metabolism. J Proteomics 2013;94:279-288.
63.
Vettukattil R, Hetland TE, Flørenes VA, Kærn J, Davidson B, Bathen TF: Proton magnetic resonance metabolomic characterization of ovarian serous carcinoma effusions: chemotherapy-related effects and comparison with malignant mesothelioma and breast carcinoma. Hum Pathol 2013;44:1859-1866.
64.
Barantin L, Pape AL, Akoka S: A new method for absolute quantitation MRS metabolites. Magn Reson Med 1997;38:179-182.
65.
Martínez-Bisbal MC, Monleon D, Assemat O, Piotto M, Piquer J, Llácer JL, et al: Determination of metabolite concentrations in human brain tumour biopsy samples using HR-MAS and ERETIC measurements. NMR Biomed 2009;22:199-206.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.